Gene editing gets its glamour from a single verb: cut. The public story of the field, the one that won a Nobel and moved markets, is a story about switching a broken gene off, silencing the thing that hurts you, deleting the line of code. Epitome Therapeutics, a Vienna biotech that came out of the shadows this week with €4 million in total funding, is built on the least cinematic idea in the whole discipline. It does not want to switch genes off. It wants to set them, precisely, to the level a healthy body would have chosen, and it thinks the largest untreated category of genetic disease lives not in the genes that scream but in the ones that have gone too quiet.
The launch capital breaks into two halves that say something about where deep-science money in Europe actually comes from. Two million euros is an oversubscribed pre-seed co-led by XISTA Science Ventures, the fund embedded in Austria’s Institute of Science and Technology, and Caesar Ventures, a Munich firm that likes to write the first cheque before anyone else will, with Navec Venture Holding also in. The other two million is competitive grant money from Austrian public programmes. That is the standard European deep-tech assembly: a science-native seed fund, a first-cheque generalist, and the state, stacked together because no one of them will carry a pre-clinical platform alone.
The whole pitch rests on a distinction most people would call a technicality
Current genetic medicine is very good at the extremes. You can knock a gene out, and the newer silencing approaches can turn its volume down. What is harder, and what Epitome is chasing, is the opposite move: turning a gene’s activity up, or holding it at a specific setting, without touching the DNA sequence at all. Its platform, CADENCE, edits the epigenome rather than the genome, using a modular set of what the company calls epigenetic effectors to activate expression in a way it describes as precise, durable and tunable to a particular biological context. Chief scientific officer Jamie Hackett, who ran a group at the EMBL research institute in Rome before co-founding the company, framed the premise as a correction to how the field talks. “Genes do not simply need to be on or off,” he said. “What matters is that they are expressed at exactly the right level.” Many diseases, on his account, are what happens when that dial has slipped.
The science is not a slide. The technology is licensed exclusively from EMBL and rests on work published in Nature Genetics in 2024, and the company was spun out in 2025 by Hackett and chief executive Guido Gualdoni, a physician-scientist, on the strength of it. That is the shape European academic biotech is supposed to have and often does not manage: a real paper, a named institution, an exclusive licence, and two founders who can respectively run the lab and the cap table. The €2 million is meant to carry CADENCE from platform to a first named drug candidate, broaden the toolkit of effectors, and hire the team that turns a mechanism into a pipeline.
Everyone in this field is fighting the same enemy, and it is not each other
The competitive frame is genuine and mostly American. Epigenetic editing has become a crowded, well-funded lane, with US companies raising large rounds to do adjacent things, and a European pre-seed of two million euros is a very small boat to launch into it. Set that against Epitome and the honest reading is that it is not remotely capitalised to win a race on money. Its wager is narrower and more defensible: that precise, tunable upregulation is a distinct problem from the silencing that most of the field has crowded into, and that owning the harder direction early is worth more than being the fifth company doing the easy one.
The risk is the one every genetic-medicine platform carries, and no amount of elegant biology waves it away. The company has a mechanism, a licence and a paper, and it does not yet have a drug candidate, a delivery answer, or a single result in a human being. Getting an epigenetic editor into the right cells, having it stay there, and having the effect last without switching something else by accident, is the part that has humbled better-funded teams than this one. Two million euros buys the right to try, not the answer. XISTA’s Alexander Schwartz, explaining the cheque, said what impressed the fund was “the focus on targeted upregulation” and the team’s plan to move the science into real programmes, which is a polite way of saying the bet is on the direction and the people, because the data is still ahead.
That is the reversal worth sitting with. The field built its reputation on the loud, decisive act of cutting a gene out, and the founders who came out of it are quietly convinced that the value was hiding in the opposite gesture all along, in the patient work of turning something back up to exactly where it should have been. Epitome has four million euros and a licence to find out whether the least dramatic idea in gene editing is also the most useful one. The dramatic version got the Nobel. The company is betting the dial was the point.